PIM1 and plasma cell myeloma: Accordingly, several Pim inhibitor molecules such as AZD 1208 or PIM447 (formerly LGH447) are currently tested in phase 1 clinical trials for multiple myeloma therapy (https://clinicaltrials.gov).